Oxidative Medicine and Cellular Longevity / 2020 / Article / Fig 6

Research Article

New Synthetic 3-Benzoyl-5-Hydroxy-2H-Chromen-2-One (LM-031) Inhibits Polyglutamine Aggregation and Promotes Neurite Outgrowth through Enhancement of CREB, NRF2, and Reduction of AMPKα in SCA17 Cell Models

Figure 6

AMPKα as a therapeutic target in LM-031-treated TBP/Q79-GFP-expressing SH-SY5Y cells. (a) Experimental flow chart. TBP/Q79-GFP SH-SY5Y cells were plated with retinoic acid (10 μM) added on day 1. The next day, LM-031 or licochalcone A (100 nM) was added to the cells. At 4 h postcompound treatment, AICAR (0.1 mM) was added to the cells for 4 h followed by inducing TBP/Q79-GFP expression (Dox, 5 μg/mL) for 6 days. On day 9, the cells were collected for AMPKα and pAMPKα protein analysis (by Western blot, GAPDH as a loading control) or stained with Hoechst 33342 for aggregation and neurite outgrowth analyses (by HCA). (b) Western blot analysis of AMPKα and pAMPKα protein levels in LM-031 or licochalcone A-treated cells treated with AICAR. To normalize, the relative AMPKα or pAMPKα level of AICAR-untreated cells without inducing TBP/Q79-GFP expression was set as 100%. values: comparisons between induced versus uninduced cells (##), compound-treated versus untreated cells (, ), or AICAR-treated versus untreated cells (&) (). (c) Aggregation and (d) neurite outgrowth assays of LM-031 or licochalcone A-treated TBP/Q79-GFP SH-SY5Y cells treated with AICAR. values: comparisons between compound-treated versus untreated cells () or AICAR-treated versus untreated cells (&, &&) (). (e) Representative microscopy images of TBP/Q79-GFP-expressing SH-SY5Y cells treated with LM-031 or licochalcone A, and AICAR-treated cells treated with LM-031 or licochalcone A. Aggregates were marked in red (left) and neurites and cell bodies were outlined (right) for outgrowth quantification.
(a)
(b)
(c)
(d)
(e)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.